NCT00114361View on ClinicalTrials.gov

48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

April 30, 2010

Conditions
Hepatitis B
Interventions
DRUG

Ribavirin

1200 mg a day, 48 weeks

DRUG

Peginterferon alpha 2a

180 µg per week, 48 weeks

Trial Locations (1)

3000CA

Erasmus MC department hepatology, Rotterdam

Sponsors
All Listed Sponsors
lead

Foundation for Liver Research

OTHER